News Image

NASDAQ:HALO, a strong growth stock, setting up for a breakout.

By Mill Chart

Last update: Jan 31, 2024

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

Understanding NASDAQ:HALO's Growth Score

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:HALO has earned a 8 for growth:

  • The Earnings Per Share has grown by an nice 12.96% over the past year.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 42.34% on average per year.
  • The Revenue has grown by 34.42% in the past year. This is a very strong growth!
  • HALO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.83% yearly.
  • The Earnings Per Share is expected to grow by 25.42% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.

Health Assessment of NASDAQ:HALO

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has achieved a 7 out of 10:

  • HALO has an Altman-Z score of 3.24. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.24, HALO is doing good in the industry, outperforming 72.68% of the companies in the same industry.
  • With an excellent Debt to FCF ratio value of 4.24, HALO belongs to the best of the industry, outperforming 94.94% of the companies in the same industry.
  • A Current Ratio of 7.63 indicates that HALO has no problem at all paying its short term obligations.
  • The Current ratio of HALO (7.63) is better than 68.13% of its industry peers.
  • A Quick Ratio of 6.51 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Quick ratio of 6.51. This is in the better half of the industry: HALO outperforms 62.06% of its industry peers.

Understanding NASDAQ:HALO's Profitability

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 8 for profitability:

  • The Return On Assets of HALO (13.41%) is better than 98.65% of its industry peers.
  • HALO's Return On Equity of 101.89% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
  • HALO has a Return On Invested Capital of 14.39%. This is amongst the best in the industry. HALO outperforms 97.64% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is significantly above the industry average of 13.65%.
  • The 3 year average ROIC (36.78%) for HALO is well above the current ROIC(14.39%). The reason for the recent decline needs to be investigated.
  • HALO's Profit Margin of 32.53% is amongst the best of the industry. HALO outperforms 98.48% of its industry peers.
  • HALO's Profit Margin has improved in the last couple of years.
  • HALO has a better Operating Margin (40.35%) than 98.99% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • HALO has a better Gross Margin (76.68%) than 85.50% of its industry peers.

Looking at the Setup

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:HALO scores a 7 out of 10:

HALO has a bad technical rating, but it does show a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period.

More Strong Growth stocks can be found in our Strong Growth screener.

Check the latest full fundamental report of HALO for a complete fundamental analysis.

Our latest full technical report of HALO contains the most current technical analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/29/2024, 7:08:09 PM)

After market: 41.8 -0.96 (-2.25%)

42.76

-0.32 (-0.74%)

HALO News

News Imagea day ago - ChartmillNASDAQ:HALO is probably undervalued for the fundamentals it is displaying.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image9 days ago - Halozyme Therapeutics, Inc.Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

News Image13 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image14 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image16 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image16 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image21 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image22 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image22 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image22 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

HALO Links
Follow us for more